Indian patients go to court over cancer drug.
作者信息
Murdur Ganapati
出版信息
BMJ. 2004 Aug 21;329(7463):419. doi: 10.1136/bmj.329.7463.419.
Abstract
摘要
相似文献
1
Indian patients go to court over cancer drug.
BMJ. 2004 Aug 21;329(7463):419. doi: 10.1136/bmj.329.7463.419.
2
Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?
Nat Clin Pract Oncol. 2005 Mar;2(3):126-7. doi: 10.1038/ncponc0110.
3
Chronic myelogenous leukaemia market.
Nat Rev Drug Discov. 2009 Jun;8(6):447. doi: 10.1038/nrd2873.
4
Can grapefruit juice decrease the cost of imatinib for the treatment of chronic myelogenous leukemia?
Leuk Res. 2011 Jan;35(1):e11-2. doi: 10.1016/j.leukres.2010.09.014. Epub 2010 Oct 16.
5
Taking TRIPS to India--Novartis, patent law, and access to medicines.
N Engl J Med. 2007 Feb 8;356(6):541-3. doi: 10.1056/NEJMp068245.
6
[Economic burden for patients with chronic myelogenous leukemia--healthcare economics and medical governance of cancer].
Gan To Kagaku Ryoho. 2010 Apr;37(4):577-81.
7
Medicine. Shortages of cancer drugs put patients, trials at risk.
Science. 2011 Apr 29;332(6029):523. doi: 10.1126/science.332.6029.523.
8
Increasing access to care for chronic myeloid leukemia patients: assessment of a scaling-up program.
J Health Care Poor Underserved. 2013 Nov;24(4):1486-97. doi: 10.1353/hpu.2013.0160.
9
Is India ready to lead the battle for fair access to medicines?
Lancet Oncol. 2013 May;14(6):437. doi: 10.1016/S1470-2045(13)70197-9.
10
Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe--impact of cost considerations.
Leukemia. 2007 Mar;21(3):383-6. doi: 10.1038/sj.leu.2404509.
Zotero 插件